Bioceros has developed a portfolio of high producing cell lines expressing biosimilar proteins, such as fusion proteins, enzymes and monoclonal antibodies which are available for out-licensing.
These biosimilar cell lines are generated on our proprietary CHO-based platform, CHOBC® using (animal component free) of the shelf culture medium. The cell lines are GMP-ready, stable, high producing, fully documented and functionally characterized. All available QA approved documentation is accessible for our (potential) partners via a Virtual Data Room.
Biosimilar programs that are completed and ready for tech transfer to a CMO of choice by our partner, as well as programs in different development stages, can be found in the table below.